|
|
Article: Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene.
- Article from:
- Clinical Trials Week
- Article date:
- November 9, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, announced issuance of Japanese Patent Number: 4354633, titled, "Hypoxia regulated genes," on August 7, 2009. Granted to Quark from a Japanese National Phase application of International (PCT) Patent Application No. PCT/US98/17296, the patent corresponds to U.S. Patent No.s 6,455,674, 6,555,667 and 6,740,738 issued by the United States Patent and Trademark Office (see also Patents).
The granted claims broadly cover various aspects of the RTP801 gene, including inhibitors targeting either the mRNA or peptide products ...
Related newspaper, magazine, and journal articles:
|
|
Article: Quark Pharmaceuticals Files Patent Application ...
PR Newswire;
August 27, 2007 ;
700+ words
... ... PRNewswire/ -- Quark Pharmaceuticals, Inc., a clinical ... pipeline products. About Quark Pharmaceuticals, Inc. Quark Pharmaceuticals is a clinical-stage ... wet age-related macular degeneration, and AKIi-5 for ...
|
|